Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research

Phenotypes of disease severity in a cohort of hospitalized COVID-19 patients: Results from the IMPACC study.

  • 2022-09
  • EBioMedicine 83
    • Al Ozonoff
    • Joanna Schaenman
    • Naresh Doni Jayavelu
    • Carly E Milliren
    • Carolyn S Calfee
    • Charles B Cairns
    • Monica Kraft
    • Lindsey R Baden
    • Albert C Shaw
    • Florian Krammer
    • Harm van Bakel
    • Denise A Esserman
    • Shanshan Liu
    • Ana Fernandez Sesma
    • Viviana Simon
    • David A Hafler
    • Ruth R Montgomery
    • Steven H Kleinstein
    • Ofer Levy
    • Christian Bime
    • Elias K Haddad
    • David J Erle
    • Bali Pulendran
    • Kari C Nadeau
    • Mark M Davis
    • Catherine L Hough
    • William B Messer
    • Nelson I Agudelo Higuita
    • Jordan P Metcalf
    • Mark A Atkinson
    • Scott C Brakenridge
    • David Corry
    • Farrah Kheradmand
    • Lauren I R Ehrlich
    • Esther Melamed
    • Grace A McComsey
    • Rafick Sekaly
    • Joann Diray-Arce
    • Bjoern Peters
    • Alison D Augustine
    • Elaine F Reed
    • Matthew C Altman
    • Patrice M Becker
    • Nadine Rouphael

Study Design

Type
Observational
Sample size
n = 1,164
Population
1164 patients from 20 hospitals across the United States
Methods
Prospective, observational study; immunophenotyping; disease severity assessed using a 7-point ordinal scale; multivariable logistic regression
Duration
1 year after discharge
Funding
Independent

Background

Better understanding of the association between characteristics of patients hospitalized with coronavirus disease 2019 (COVID-19) and outcome is needed to further improve upon patient management.

Methods

Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC) is a prospective, observational study of 1164 patients from 20 hospitals across the United States. Disease severity was assessed using a 7-point ordinal scale based on degree of respiratory illness. Patients were prospectively surveyed for 1 year after discharge for post-acute sequalae of COVID-19 (PASC) through quarterly surveys. Demographics, comorbidities, radiographic findings, clinical laboratory values, SARS-CoV-2 PCR and serology were captured over a 28-day period. Multivariable logistic regression was performed.

Findings

The median age was 59 years (interquartile range [IQR] 20); 711 (61%) were men; overall mortality was 14%, and 228 (20%) required invasive mechanical ventilation. Unsupervised clustering of ordinal score over time revealed distinct disease course trajectories. Risk factors associated with prolonged hospitalization or death by day 28 included age ≥ 65 years (odds ratio [OR], 2.01; 95% CI 1.28-3.17), Hispanic ethnicity (OR, 1.71; 95% CI 1.13-2.57), elevated baseline creatinine (OR 2.80; 95% CI 1.63- 4.80) or troponin (OR 1.89; 95% 1.03-3.47), baseline lymphopenia (OR 2.19; 95% CI 1.61-2.97), presence of infiltrate by chest imaging (OR 3.16; 95% CI 1.96-5.10), and high SARS-CoV2 viral load (OR 1.53; 95% CI 1.17-2.00). Fatal cases had the lowest ratio of SARS-CoV-2 antibody to viral load levels compared to other trajectories over time (p=0.001). 589 survivors (51%) completed at least one survey at follow-up with 305 (52%) having at least one symptom consistent with PASC, most commonly dyspnea (56% among symptomatic patients). Female sex was the only associated risk factor for PASC.

Interpretation

Integration of PCR cycle threshold, and antibody values with demographics, comorbidities, and laboratory/radiographic findings identified risk factors for 28-day outcome severity, though only female sex was associated with PASC. Longitudinal clinical phenotyping offers important insights, and provides a framework for immunophenotyping for acute and long COVID-19.

Funding

NIH.

Research Insights

    Back to top